Triple
T11553575
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Patrick Soon-Shiong |
E273954
|
entity |
| Predicate | founded |
P104
|
FINISHED |
| Object |
Abraxis BioScience
Abraxis BioScience was a biopharmaceutical company best known for developing the cancer drug Abraxane and focusing on nanoparticle-based chemotherapy treatments.
|
E932802
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Abraxis BioScience | Statement: [Patrick Soon-Shiong, founded, Abraxis BioScience]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Abraxis BioScience Context triple: [Patrick Soon-Shiong, founded, Abraxis BioScience]
-
A.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
B.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
-
C.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
D.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
E.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Abraxis BioScience Triple: [Patrick Soon-Shiong, founded, Abraxis BioScience]
Generated description
Abraxis BioScience was a biopharmaceutical company best known for developing the cancer drug Abraxane and focusing on nanoparticle-based chemotherapy treatments.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Abraxis BioScience Target entity description: Abraxis BioScience was a biopharmaceutical company best known for developing the cancer drug Abraxane and focusing on nanoparticle-based chemotherapy treatments.
-
A.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
B.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
-
C.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
D.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
E.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d6aae4dfa48190a3ab0b19a159a3c5 |
completed | April 8, 2026, 7:22 p.m. |
| NER | Named-entity recognition | batch_69d88a85b9ac8190a57c1fdaeacbe3d6 |
completed | April 10, 2026, 5:28 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69e6e851a6688190996580a077496833 |
completed | April 21, 2026, 3 a.m. |
| NEDg | Description generation | batch_69e6ef93e7d88190af3853b82de23c1b |
completed | April 21, 2026, 3:31 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69e6f9144afc819081ee7f78e32ad39a |
completed | April 21, 2026, 4:12 a.m. |
Created at: April 8, 2026, 9:37 p.m.